brii-179
Vaccineexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 12, 2021 (NCT04749368)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Hepatitis B virusImmunity, active
Hepatitis B virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06650852 | Phase 2 | Nov 30, 2024 | Brii Biosciences |
| NCT06491563 | Phase 2 | Aug 31, 2024 | Brii Biosciences, Vir Biotechnology, Inc. |
| NCT04749368 | Phase 2 | Apr 12, 2021 | Brii Biosciences, VBI Vaccines Inc., Vir Biotechnology, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Brii Biosciences | For profit | 3 | 3 | 1 | 2021 |
| Vir Biotechnology, Inc. | For profit | 2 | 0 | 1 | 2021 |
| VBI Vaccines Inc. | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1